Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

ClinicalTrials.gov ID: NCT03503318

Public ClinicalTrials.gov record NCT03503318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent participants with schizophrenia. The study will include male and female participants, 13 to 65 years of age, who have a confirmed diagnosis of schizophrenia, are clinically stable, and are eligible for risperidone treatment

Study identification

NCT ID
NCT03503318
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
544 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
13 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 26, 2018
Primary completion
Sep 29, 2020
Completion
Dec 2, 2020
Last update posted
Mar 9, 2023

2018 – 2020

United States locations

U.S. sites
73
U.S. states
18
U.S. cities
61
Facility City State ZIP Site status
Teva Investigational Site 14769 Little Rock Arkansas 72211
Teva Investigational Site 14796 Rogers Arkansas 72758
Teva Investigational Site 14811 Anaheim California 92805
Teva Investigational Site 14794 Bellflower California 90706
Teva Investigational Site 14776 Colton California 92324
Teva Investigational Site 14767 Costa Mesa California 92626
Teva Investigational Site 14802 Costa Mesa California 92627
Teva Investigational Site 14773 Culver City California 90230
Teva Investigational Site 14835 Garden Grove California 92845
Teva Investigational Site 14774 Glendale California 91206
Teva Investigational Site 14817 La Habra California 90631
Teva Investigational Site 14771 Lemon Grove California 91945
Teva Investigational Site 14823 Long Beach California 90822
Teva Investigational Site 14816 Montclair California 91763
Teva Investigational Site 14803 Norwalk California 90650
Teva Investigational Site 14786 Oakland California 94607
Teva Investigational Site 14797 Oceanside California 92054
Teva Investigational Site 14827 Oceanside California 92056-4515
Teva Investigational Site 14777 Orange California 92868
Teva Investigational Site 14815 Pico Rivera California 90660
Teva Investigational Site 14812 Riverside California 92506
Teva Investigational Site 14785 San Bernardino California 92408
Teva Investigational Site 14818 San Diego California 92103
Teva Investigational Site 14828 San Diego California 92103
Teva Investigational Site 14819 San Marcos California 92078
Teva Investigational Site 14779 Santa Ana California 92705
Teva Investigational Site 14788 Torrance California 90502
Teva Investigational Site 14768 Coral Gables Florida 33134
Teva Investigational Site 14783 Coral Gables Florida 33134
Teva Investigational Site 14836 Hallandale Florida 33009
Teva Investigational Site 14787 Hialeah Florida 33016
Teva Investigational Site 14814 Hialeah Florida 33018
Teva Investigational Site 14799 Lauderhill Florida 33319
Teva Investigational Site 14832 Miami Florida 33126
Teva Investigational Site 14810 North Miami Florida 33161
Teva Investigational Site 14831 Orange City Florida 32763
Teva Investigational Site 14806 Orlando Florida 32810
Teva Investigational Site 14837 Tampa Florida 33614
Teva Investigational Site 14824 Atlanta Georgia 30331
Teva Investigational Site 14834 Columbus Georgia 31904
Teva Investigational Site 14821 Decatur Georgia 30030
Teva Investigational Site 14770 Marietta Georgia 30060
Teva Investigational Site 14765 Chicago Illinois 60612
Teva Investigational Site 14829 Chicago Illinois 60640
Teva Investigational Site 14805 Hoffman Estates Illinois 60169
Teva Investigational Site 14825 Shreveport Louisiana 71101
Teva Investigational Site 14764 Glen Burnie Maryland 21061
Teva Investigational Site 14820 New Bedford Massachusetts 02740
Teva Investigational Site 14798 Saginaw Michigan 48603
Teva Investigational Site 14791 St Louis Missouri 63109
Teva Investigational Site 14813 St Louis Missouri 63128
Teva Investigational Site 14826 St Louis Missouri 63132
Teva Investigational Site 14790 St Louis Missouri 63141
Teva Investigational Site 14809 Las Vegas Nevada 89102
Teva Investigational Site 14792 Berlin New Jersey 08009
Teva Investigational Site 14830 Princeton New Jersey 08540
Teva Investigational Site 14772 Cedarhurst New York 11516
Teva Investigational Site 14804 New York New York 10029
Teva Investigational Site 14800 New York New York 10032
Teva Investigational Site 14784 New York New York 10036
Teva Investigational Site 14780 Staten Island New York 10312
Teva Investigational Site 14763 Cincinnati Ohio 45219
Teva Investigational Site 14782 Dayton Ohio 45417
Teva Investigational Site 14822 Oklahoma City Oklahoma 73112
Teva Investigational Site 14789 Allentown Pennsylvania 18104
Teva Investigational Site 14833 Norristown Pennsylvania 19403
Teva Investigational Site 14775 Scranton Pennsylvania 18503
Teva Investigational Site 14793 Thorndale Pennsylvania 19372
Teva Investigational Site 14778 Charleston South Carolina 29407
Teva Investigational Site 14781 Dallas Texas 75231
Teva Investigational Site 14766 Dallas Texas 75243
Teva Investigational Site 14801 Houston Texas 77081
Teva Investigational Site 14807 Irving Texas 75062

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

Recently updated Schizophrenia trials

Other public records listing Schizophrenia. Sorted by last update posted; newest first. Not a recommendation.

All Schizophrenia trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03503318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2023 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03503318 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →